Literature DB >> 8002083

Early- and late-onset pelvic inflammatory disease among women with cervical Chlamydia trachomatis infection at the time of induced abortion--a follow-up study.

J L Sørensen1, I Thranov, G Hoff, J Dirach.   

Abstract

After termination of a double-blind, randomized study on erythromycin in the prevention of post-abortion infection, 34 women (14 treated with erythromycin, 20 not treated with erythromycin) harbouring Chlamydia trachomatis were followed up within 6 weeks and again 2 to 24 months after the abortion in order to detect an early- and late-onset pelvic inflammatory disease (PID). For statistical analysis survival analysis by Kaplan-Meir estimates and Mantel-Cox test were carried out. Untreated women with C. trachomatis infection at the time of abortion had a cumulative risk of 72% of developing early and/or late PID, if observed for 24 months. This cumulative risk was significantly reduced to 8% if the C. trachomatis infection was treated at the time of the abortion. Screening for and treatment of C. trachomatis is warranted, especially in women < or = 25 years old, to avoid early and late-onset PID after induced first trimester abortion.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8002083     DOI: 10.1007/BF01739907

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  20 in total

1.  [Prevalence of positive gonococcal and chlamydial findings in women applying for termination of pregnancy. A screening evaluation].

Authors:  J C Prien-Larsen; J J Kjer
Journal:  Ugeskr Laeger       Date:  1989-06-26

Review 2.  Impact of abortion on subsequent fecundity.

Authors:  C J Hogue
Journal:  Clin Obstet Gynaecol       Date:  1986-03

3.  A double-blind randomized study of the effect of erythromycin in preventing pelvic inflammatory disease after first trimester abortion.

Authors:  J L Sørensen; I Thranov; G Hoff; J Dirach; M T Damsgaard
Journal:  Br J Obstet Gynaecol       Date:  1992-05

4.  Postabortal endometritis and isolation of Chlamydia trachomatis.

Authors:  M B Barbacci; M R Spence; E W Kappus; R C Burkman; L Rao; T C Quinn
Journal:  Obstet Gynecol       Date:  1986-11       Impact factor: 7.661

5.  Induced abortion: microbiological screening and medical complications.

Authors:  B Stray-Pedersen; J Biørnstad; M Dahl; T Bergan; G Aanestad; L Kristiansen; K Hansen
Journal:  Infection       Date:  1991 Sep-Oct       Impact factor: 3.553

6.  Epidemiology of chlamydial infection of the human genital tract: evidence for the existence of latent infections.

Authors:  J D Oriel; G L Ridgway
Journal:  Eur J Clin Microbiol       Date:  1982-04       Impact factor: 3.267

7.  Contact-tracing in patients with genital chlamydial infection.

Authors:  I Thelin; A M Wennström; P A Mårdh
Journal:  Br J Vener Dis       Date:  1980-08

8.  Ectopic pregnancy and antibodies to Chlamydia trachomatis.

Authors:  L Svensson; P A Mårdh; M Ahlgren; F Nordenskjöld
Journal:  Fertil Steril       Date:  1985-09       Impact factor: 7.329

9.  Therapeutic abortion and Chlamydia trachomatis infection.

Authors:  E Qvigstad; K Skaug; F Jerve; I S Vik; J C Ulstrup
Journal:  Br J Vener Dis       Date:  1982-06

10.  A prospective study of Chlamydia trachomatis in first trimester abortion.

Authors:  H Shioøtz; P A Csángó
Journal:  Ann Clin Res       Date:  1985
View more
  3 in total

1.  Influence of material deprivation on hospital admissions for gynaecologic infections.

Authors:  B Olowokure; J I Hawker; S Harcourt; F Warburton; J Weinberg; R C Wilson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-06-25       Impact factor: 3.267

Review 2.  Controversies in family planning: postabortal pelvic inflammatory disease.

Authors:  Jennefer A Russo; Sharon Achilles; Teresa DePineres; Laura Gil
Journal:  Contraception       Date:  2012-05-29       Impact factor: 3.375

3.  Estimating Local Chlamydia Incidence and Prevalence Using Surveillance Data.

Authors:  Joanna Lewis; Peter J White
Journal:  Epidemiology       Date:  2017-07       Impact factor: 4.822

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.